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ABSTRACT
Fibulin-2 participates in the assembly of extracellular matrix components through 
interactions with multiple ligands and promotes contacts between cells and their 
surrounding environment. Consequently, identification of processes that could lead to 
an altered Fibulin-2 could have a major impact not only in the maintenance of tissue 
architecture and morphogenesis but also in pathological situations including cancer. 
Herein, we have investigated the ability of the secreted metalloproteases ADAMTS-4 
and ADAMTS-5 to digest Fibulin-2. Using in vitro approaches and cultured breast 
cancer cell lines we demonstrate that Fibulin-2 is a better substrate for ADAMTS-5 than 
it is for ADAMTS-4. Moreover, Fibulin-2 degradation is associated to an enhancement 
of the invasive potential of T47D, MCF-7 and SK-BR-3 cells. We have also found that 
conditioned medium from MCF-7 cells that simultaneously overexpress Fibulin-2 and 
ADAMTS-5 significantly induced the migratory and invasive ability of normal breast 
fibroblasts using 3D collagen matrices. Immunohistochemical analysis highlights the 
close proximity or partial overlap of both Fibulin-2 and ADAMTS-5 in breast tumor 
samples. Additionally, proteolytic products derived from a potential degradation 
of Fibulin-2 by ADAMTS-5 were also identified in these samples. Finally, we also 
show that the cleavage of Fibulin-2 by ADAMTS-5 is counteracted by ADAMTS-12, 
a metalloprotease that interacts with Fibulin-2. Overall, our results provide direct 
evidence indicating that Fibulin-2 is a novel substrate of ADAMTS-5 and that this 
proteolysis could alter the cellular microenvironment affecting the balance between 
protumor and antitumor effects associated to both Fibulin-2 and the ADAMTSs 
metalloproteases.
INTRODUCTION
Fibulins are a family of seven secreted glycoproteins 
characterized by a complex molecular architecture [1, 2]. 
All members of this family share a variable number of 
EGF-like domains at their central portion and a fibulin-type 
module at the C-terminal region of the protein. Domains 
at the N-terminal region are the most variable among all 
members and, in the cases of Fibulin-1 and Fibulin-2, three 
anaphylatoxin domains can be identified. Additionally, 
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Fibulin-2 possesses two distinctive domains called 
Cys-rich and Cys-free segments within its N-terminal 
region. This broad variety of domains serves to establish 
interactions with multiple ECM and cell surface 
components. For instance, Fibulin-2 can interact with 
aggrecan [3], nidogen [4], fibronectin [5], and perlecan 
[6] among others, as well as cellular integrins [7], thus 
contributing to the maintenance of extracellular structures 
such as basement membranes and elastic fibers [1]. 
However, Fibulin-2 has also been involved in functions 
other than its structural role at the ECM. Thus, Fibulin-2 is 
rapidly upregulated during skin wound healing suggesting 
its participation in cell mobility and tissue repair processes 
[8]. In addition, a growing number of studies highlights 
the involvement of Fibulin-2 in tumorigenesis. In this 
regard, Fibulin-2 can display both tumor-promoting [9, 
10] and tumor-protective [11, 12] properties in different 
types of neoplasia. Mechanisms underlying these opposing 
effects are complex and not fully understood [13, 14].
Functional relevance of Fibulin-2 makes it 
paramount to identify and understand those situations 
in which the function of this secreted glycoprotein is 
altered. In this respect, previous works have revealed 
that Fibulin-2 can be proteolytically processed by MMPs 
and serine proteases involved in tissue remodeling 
processes [15], whereas its closest partner Fibulin-1 is 
more resistant to this proteolysis. Cleavage of Fibulin-2 
can occur not only during normal metabolism but also 
associated to pathological processes. As an example, 
it is known that Fibulin-2 is highly expressed in blood 
vessels and protects from vascular injuries, so it is 
possible that this glycoprotein could be degraded by 
proteases in vascular lesions [15, 16]. It has been also 
found that Fibulin-2 is degraded in photodamaged skin, 
which is attributed to an increase in the proteolytic 
activity [17]. Fibulin-2 degradation has also been 
associated to tumorigenesis in osteosarcoma [18]. In fact, 
a considerable amount of Fibulin-2 proteolytic products 
are detected in osteosarcoma cell lines in comparison with 
primary osteoblasts. Gelatinases MMP-2 and MMP-9 are 
responsible for Fibulin-2 degradation in these tumor cells. 
Furthermore, susceptibility of Fibulin-2 to the degradation 
mediated by MMP-2 has been confirmed through in vitro 
biochemical approaches [19]. By contrast, Fibulin-1 is 
also highly resistant to the proteolysis mediated by this 
gelatinase [18].
ADAMTS-4 and ADAMTS-5 are members of the 
ADAMTS family of secreted metalloproteases [20]. Both 
enzymes are also known as aggrecanases owing their ability 
to cleave cartilage aggrecan [21]. Additionally, aggrecanases 
can also degrade ECM components other than aggrecan, 
such as brevican [22], biglycan [23], versican [24], a2-
macroglobulin [25] or matrilin-2 [26]. This broad spectrum 
of substrates highlights the importance of ADAMTS-4 
and ADAMTS-5 in key physiological processes [27, 28], 
as well as in pathological disorders including osteoarthritic 
diseases [29] and cancer [20, 30]. In this work we show that 
the aggrecanases, mainly ADAMTS-5, can cleave Fibulin-2 
both in vitro and in cultured breast cancer cell lines. 
Moreover, Fibulin-2 digestion increases the tumorigenic 
potential of the poorly invasive T47D and MCF-7 cell lines. 
We have also investigated the localization of both Fibulin-2 
and ADAMTS-5 in breast cancer samples as well as the 
effect that the conditioned medium of breast cancer cells 
that exogenously express Fibulin-2 alone or in combination 
with ADAMTS-5 produces on normal mammary fibroblasts. 
In addition, we have also found that Fibulin-2 degradation 
by ADAMTS-5 can be blocked by ADAMTS-12, another 
member of the ADAMTS family of metalloproteases that 
interacts with and enhances the antitumor effects mediated 
by Fibulin-2 [31]. Our data strongly suggest that the 
cleavage by aggrecanases, but especially by ADAMTS-5, 
could influence the balance between pro- and anti-tumor 
effects elicited by Fibulin-2.
RESULTS
Proteolytic digestion of Fibulin-2 by 
aggrecanases
As part of our work aimed at identifying new 
interactions between ADAMTS metalloproteases 
and ECM components, we found that Fibulin-2 is a 
novel substrate for the ADAMTS-4 and ADAMTS-5 
metalloproteases. As can be seen in Figure 1A, incubation 
of Fibulin-2 with these proteolytic enzymes resulted 
in its degradation. This analysis also suggested that 
ADAMTS-5 could be more effective than ADAMTS-4 
at cleaving Fibulin-2 attending to the reduced intensity 
of the major immunoreactive band that corresponds 
to the entire Fibulin-2 and to the accumulation of a 
main proteolytic product of about 50 kDa using same 
enzyme concentrations and incubation times. In this 
assay, we also wanted to evaluate whether ADAMTS-1 
was also able to degrade Fibulin-2 taking into account 
that ADAMTS-1, ADAMTS-4 and ADAMTS-5 share 
the ability to digest not only aggrecan but also other 
hyalectans such as versican or neurocan [32]. However, 
Fibulin-2 was not cleaved by ADAMTS-1 under the 
same experimental conditions (Figure 1A). We also 
examined whether the 50 kDa band could be the final 
degradation product. Following 24 h incubation with 
either ADAMTS-4 or ADAMTS-5 entire Fibulin-2 was 
not detected and the 50 kDa band was the only detectable 
band by ADAMTS-5 proteolysis and one of the main 
proteolytic products by ADAMTS-4 proteolytic activity 
(Figure 1A). These data would indicate that the 50 kDa 
fragment is the consequence of a specific proteolysis 
rather than the result of a non-specific degradation by the 
aggrecanases.
Next, we examined the possibility that the cleavage 
of Fibulin-2 mediated by aggrecanases could occur in 
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cultured cells. To this end, we used MCF-7 cells, a breast 
cancer cell line that does not express Fibulin-2 [12]. 
Following co-transfection with a vector containing the 
full-length cDNA for Fibulin-2 together with a vector 
containing the full-length cDNA for either ADAMTS-4 
or ADAMTS-5, cell extracts were analyzed by western 
blot, and we found that Fibulin-2 resulted proteolytically 
cleaved in the presence of the aggrecanases but especially 
by ADAMTS-5 (Figure 1B).
To elucidate whether endogenous Fibulin-2 could 
also be degraded by these proteases, we carried out 
transfections only with plasmids containing the full-length 
cDNA for ADAMTS-4 or ADAMTS-5 into SK-BR-3 breast 
cancer cells, which endogenously express Fibulin-2 [12]. 
Results again highlighted the ability of both aggrecanases 
to digest Fibulin-2, particularly ADAMTS-5 (Figure 1B). 
These data suggest that the proteolysis of Fibulin-2 by 
these metalloproteases may also occur in vivo.
MCF-7 cells were also employed to ascertain that 
ADAMTS-1 does not digest Fibulin-2 in culture cells. 
Following co-transfection with the corresponding cDNAs 
our result revealed that Fibulin-2 remains mostly intact as 
assessed by western blot (Supplementary Figure 1A). In 
addition, we employed HEK293 cells attending to their 
high efficiency of transformation to examine whether 
Fibulin-2 degradation products can be detected as soluble 
fragments in cell conditioned medium. Western blot 
analysis pointed out the presence of immunoreactive bands 
in conditioned medium from HEK293 cells co-transfected 
with cDNAs for Fibulin-2 and ADAMTS-5, which were 
absent in the medium from the same cell line transfected 
with only cDNA for Fibulin-2 (Supplementary Figure 1B). 
Proteolysis of Fibulin-2 by aggrecanases 
increases the invasive phenotype of MCF-7 and 
T47D breast cancer cell lines
To examine whether the degradation of Fibulin-2 
could alter the invasive potential of MCF-7 cells, we 
performed cell invasion assays using Matrigel-coated 
invasion chambers with MCF-7 cells expressing 
Fibulin-2 alone (MCF-7 Fib.2) or in combination 
with either ADAMTS-4 (Fib.2+ADAMTS-4) or 
ADAMTS-5 (Fib.2+ADAMTS-5). MCF-7 cells that 
express ADAMTS-4 alone or ADAMTS-5 alone were 
employed for comparative purposes, and MCF-7 
transfected with an empty vector were employed as 
control (Figure 2A and 2B). Results revealed that MCF-7 
Fib.2+ADAMTS-5 cells showed the highest capacity to 
invade (2.5-fold increase as compared with control cells), 
followed by MCF-7 ADAMTS-5 (2.0-fold), MCF-7 
Fib.2 + ADAMTS-4 (1.9-fold) and MCF-7 ADAMTS-4 
(1.3-fold). By contrast, presence of Fibulin-2 alone 
considerably reduces the ability as of MCF-7 cells (MCF-7 
Fib.2 cells) to invade through the Matrigel-coated 
invasion chambers. Similar results were obtained using 
T47D cells, other breast cancer cell line that does not 
express Fibulin-2 [12]. Following transfection with the 
corresponding full-length cDNAs to express the indicated 
recombinant proteins (Supplementary Figure 2A), we 
performed invasion assays to determine that T47D 
Fib.2+ADAMTS-5 cells showed the highest increase (3.4-
fold), followed by T47D Fib.2+ADAMTS-4 (2.3-fold), 
T47D ADAMTS-5 (2.0-fold) and T47D ADAMTS-4 
(1.9-fold) cells as compared with T47D control cells. 
Presence of Fibulin-2 alone impeded T47D cells to 
invade as T47D Fib.2 cells were barely detected in the 
lower surface of the invasion chamber (Supplementary 
Figure 2B). It was also noticeable the morphological 
change undergone by T47D cells expressing Fibulin-2 
with ADAMTS-4 or ADAMTS-5. In fact, T47D is a cell 
line that exhibits an epithelial-like morphology [33, 34]. 
However simultaneous presence of Fibulin-2 and an 
aggrecanase, mainly ADAMTS-5, induced morphological 
changes in T47D cells from cobblestone-like to spindle-
like shape (Supplementary Figure 2C). This effect has 
been associated to an epithelial-mesenchymal transition 
process in T47D cells [34]. Taking together, these results 
illustrate that Fibulin-2 can influence breast cancer cell 
behavior depending on the presence of aggrecanases.
Effect of tumor cell-conditioned media on 
mammary fibroblast spheroids
Taking into account previous results showing 
that ADAMTS-5 induces more significant differences 
on breast cancer cells behavior than ADAMTS-4, we 
focused our further efforts on ADAMTS-5 through the 
examination of the effect of different conditioned media 
on normal mammary fibroblasts. We first verified that 
the mammary fibroblasts employed in this study produce 
Fibulin-2 (Supplementary Figure 3), as it has been 
previously demonstrated for human skin and embryonic 
fibroblasts [35]. Then different conditioned media from 
MCF-7 cells, which showed a low level of endogenous 
ADAMTS-5 expression among the three breast cancer cell 
lines employed in this work (Supplementary Figure 3), 
were added to normal mammary fibroblasts spheroids 
embedded in 3D collagen matrix (Figure 3A and 3B, and 
Supplementary Videos 1 to 5). Result revealed that the 
exposure of spheroids to conditioned medium from MCF-7 
ADAMTS-5 cells induced an extensive branching (3.9-fold 
change at 20 hours) expanding into the surrounding 
matrix (invasive area). Fibroblasts spheroids exposed 
to conditioned medium from MCF-7 transfected with 
an empty vector or to medium alone (control condition) 
showed 2.8-fold and 2.6-fold increase in their invasive 
areas respectively; whereas conditioned medium from 
MCF-7 Fib.2 cells induced the lowest increase in the 
spheroids invasive area (2.2-fold) at the same incubation 
time. However, conditioned medium from MCF-7 cells 
that simultaneously expressed Fibulin-2 and ADAMTS-5 
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(MCF-7 Fib2+ADAMTS-5 cells) stimulated the increase 
of the invasive area 3,3-fold, value closer to that obtained 
for conditioned medium from MCF-7 ADAMTS-5 cells. 
Moreover, we found that this effect was accompanied 
by an increase in the α-SMA levels (supplementary 
Figure 4), a hallmark of stromal fibroblasts isolated from 
breast cancer tissues [36]. These results suggest that the 
protective role of Fibulin-2 can be neutralized by its 
degradation by ADAMTS-5 affecting the migratory and 
invasive potential of the stromal fibroblasts.
Detection of ADAMTS-5 and Fibulin-2 in breast 
cancer samples
We performed an immunohistochemical analysis of 
the expression of ADAMTS-5 and Fibulin-2 in a tissue 
array containing 48 invasive ductal carcinoma (IDC) tissue 
samples from different differentiation grades (14 samples 
IDC grade I, IDC-I; 6 grade I–II; 6 grade II; 4 grade II–III; 
and 18 grade III), as IDC is the most common type of 
breast cancer. Overall, our data indicate a close proximity 
Figure 1: Fibulin-2 cleavage by ADAMTS-4 and ADAMTS-5. (A) Left, in vitro digestion of Fibulin-2 by aggrecanases. Fibulin-2 
was incubated with ADAMTS-1 (Fib.2 + ADAMTS-1), ADAMTS-4 (Fib.2 + ADAMTS4) or ADAMTS-5 (Fib.2 + ADAMTS-5) for 16 h. 
Fib.2 indicates Fibulin-2 incubated alone (without metalloproteases, control). Right, an independent experiment was perfomed to evaluate 
final degradation products. To this end, Fibulin-2 was incubated for 24 h with ADAMTS-1 (Fib.2 + ADAMTS-1), ADAMTS-4 (Fib.2 + 
ADAMTS-4) or ADAMTS-5 (Fib.2 + ADAMTS-5). Main proteolytic products were detected with an anti-Fibulin-2 antibody and are 
indicated with arrows. Molecular weight markers are indicated on the left. (B) Left, MCF-7 cells were transfected with a plasmid containing 
the full-length cDNA for Fibulin-2 (Fib.2) or co-transfected with this plasmid and plasmids containing the full-length cDNA for ADAMTS-4 
(Fib.2 + ADAMTS-4), or ADAMTS-5 (Fib.2 + ADAMTS-5). SK-BR-3 produces fibulin-2 endogenously and they were transfected with 
an empty vector (C, Control), or with vector containing the full-length cDNAs for ADAMTS-4 or ADAMTS-5. Right, expression of 
exogenous ADAMTS-4 and ADAMTS-5 was analyzed by using an anti-FLAG antibody (bottom panels). Intervening irrelevant lanes are 
not shown. Molecular weight markers are indicated on the left and β-actins were used as loading control.
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Figure 2: Invasion capacity of MCF-7 is increased by the simultaneous presence of Fibulin-2 and ADAMTS-5. 
(A) Representative pictures showing invasive MCF-7 cells using Matrigel-coated invasion chambers. Control, MCF-7 cells transfected 
with an empty vector. (B) Quantification of fold-change in invasion capacity of MCF-7 cells as compared with control cells (relative values) 
under the different conditions assayed.
Figure 3: Effect of conditioned medium from MCF-7 cells on normal mammary fibroblasts spheroids in 3D collagen 
matrices. (A) Representative images of fibroblast spheroids exposed to conditioned medium from MCF-7 cells transfected with an empty 
vector (WT) or cells overexpressing Fibulin-2 (Fib.2), ADAMTS-5 (ADAMTS-5) or both (Fib.2 + ADAMTS-5) at the indicated times. 
Medium without cultured cells was employed as control medium. (B) Measure of the branching (invasive area) by the fibroblasts spheroids 
as fold-changes increases at the indicated times.
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between both proteins independently of the tumor stage 
using serial slides, but showing different intensities for 
each case. Some representative examples are indicated in 
Figure 4. For instance in a IDC-I sample, Fibulin-2 was 
faintly detected in large duct walls and periductal spaces 
(Figure 4A), whereas ADAMTS-5 immunostaining 
was also detected in large mammary ducts but showing 
a strong intensity (Figure 4B). In IDC I–II samples, 
Fibulin-2 was barely detected in tumor cell masses 
(Figure 4C) and ADAMTS-5 was present in masses of 
epithelial cells (Figure 4D). In IDC II and IDC II–III, 
Fibulin-2 was in the periductal and perivascular stroma 
(Figure 4E) or in some well delimited cells of the tumor 
cells masses (Figure 4G); whereas ADAMTS-5 showed 
a faint immunoreactivity paralleled to that of Fibulin-2 
(Figure 4F) or diffusely presented in masses of epithelial 
cells (Figure 4H). In IDC III, a strong immunoreactivity 
for both Fibulin-2 (Figure 4I and 4K) and ADAMTS-5 
(Figure 4J and 4L) was observed in the capsular stroma 
surrounding solid masses as well as diffusely distributed 
in the tissue stroma. Moreover, some tumor regions close 
to large blood vessels were encircled by ADAMTS-5 and 
Fibulin-2 positive cells. 
An immunofluorescence analysis to better examine 
the localization of both Fibulin-2 and ADAMTS-5 was 
also performed in IDC III (Figure 5). In this analysis 
ADAMTS-5 immunoreactivity was observed labeling 
the stroma (Figure 5A and 5B), whereas a faint but 
specific immunoreaction for Fibulin-2 was detected in 
the epithelial cell clusters (Figure 5C and 5D). When 
images where merged (Figure 5E to 5H) Fibulin-2 and 
ADAMTS-5 showed a close proximity or a partial but not 
a full co-localization.
Presence of Fibulin-2 and ADAMTS-5 was also 
examined by western blot in a panel of eight paired 
normal-tumor breast cancer samples with the finding 
that an immunoreactive band corresponding to the 
metalloprotease was detected in all tumor samples 
(Figure 5I). However, entire Fibulin-2 was mainly 
detected in normal tissues and an approximately 
50 kDa immunoreactive band was also discernible in 
different tumor but also in normal samples. Six breast 
tumor samples corresponding to advanced stages of the 
disease were additionally analyzed and a weak signal 
corresponding to the entire Fibulin-2 was detected in three 
samples and ADAMTS-5 was identified in most of them 
(Supplementary Figure 5). These data would indicate that 
the cleavage of Fibulin-2 by ADAMTS-5 may also occur 
in vivo. However, other factors can influence the presence 
or function of both extracellular matrix proteins and it 
might be a proteolysis process also mediated by different 
proteases. As an illustrative approach we performed an 
in vitro digestion of Fibulin-2 with ADAMTS-5 or MMP-2 
(Supplementary Figure 5). Following 4 or 10 hours 
of incubation, patterns of proteolytic digestion were 
analyzed by western blot with the finding that some of 
the immunoreactive bands could correspond to those 
identified in breast tumor samples according to their 
molecular weight. This result strongly suggests that 
Fibulin-2 cleavage in breast tumors can be mediated by 
different proteases.
ADAMTS-12 hampers the degradation of 
Fibulin-2 by ADAMTS-5
We have previously reported that ADAMTS-12 is 
an interacting partner of Fibulin-2 and that this interaction 
promotes tumor-protective effects in breast cancer cells 
[31]. In the present work we wanted to analyze whether 
ADAMTS-12 could affect Fibulin-2 cleavage by 
ADAMTS-5. To this end we incubated Fibulin-2 with 
ADAMTS-5 in the presence or absence of ADAMTS-12. 
While the degradation of Fibulin-2 by ADAMTS-5 is 
clearly observed at 8 and 16 h of incubation in the absence 
of ADAMTS-12, its presence hinders Fibulin-2 proteolysis 
(Figure 6A). Also, accumulation of the proteolytic product 
around 50 kDa is already detected at 8 h of incubation in 
the absence of ADAMTS-12, but not in its presence. To 
investigate whether the presence of ADAMTS-12 could 
affect the behavior of breast cancer cells overexpressing 
ADAMTS-5, we carried out invasion assays using SK-
BR-3 cells bearing in mind their endogenous expression 
of Fibulin-2. SK-BR-3 cells overexpressing ADAMTS-5 
increased their ability to invade when compared with SK-
BR-3 control cells (SK-BR-3c) (Figure 6B). However, 
exogenous expression of ADAMTS-12 did not only reduce 
the capacity of cells to invade but also counteracted the 
increase of the invasive capacity caused by ADAMTS-5. 
Taking into account these results, it could be hypothesized 
that ADAMTS-12 protects Fibulin-2 from the degradation 
mediated by ADAMTS-5, which could influence the 
equilibrium between tumor-promoting and tumor-
preventing functions attributed to Fibulin-2 (Figure 6C).
DISCUSSION 
In this work we found that Fibulin-2 is a novel 
substrate of the aggrecanases, in particular of ADAMTS-5. 
This can be explained by the fact that ADAMTS-5 has a 
higher intrinsic catalytic ability than that of ADAMTS-4 
[37]. In this sense, ADAMTS-5 shows much higher 
aggrecanolytic activity than ADAMTS-4 [38]. This 
observation could be of interest in relation to the tumor-
protective and tumor-promoting effects associated to both 
Fibulin-2 [13, 14] and the ADAMTS metalloproteases 
[20, 30]. Thus, it can be hypothesized that cleavage of 
Fibulin-2 by ADAMTS-5 could form part of the strategies 
employed by tumor cells to degrade ECM components 
thereby facilitating tumor cell invasion. In this regard, 
degradation of two well-known ADAMTS-5 substrates 
such as brevican [39] and aggrecan [40] facilitate tumor 
progression in glioblastoma and laryngeal carcinoma, 
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respectively. Of note, ADAMTS-4 is expressed at lower 
level than ADAMTS-5 in tumors of the larynx [40] and 
in the metastatic loci of head and neck cancers [41]. This 
could indicate that ADAMTS-4 exerts a less relevant role 
than ADAMTS-5 in the metastatic processes of certain 
tumor types. Moreover, our results also indicate that 
Fibulin-2 is not a substrate of ADAMTS-1. Interestingly, 
it has been previously shown that Fibulin-1, the closest 
partner of Fibulin-2, is not a substrate but it can act as 
a cofactor of ADAMTS-1 [42]. As happens with most 
of the members of the family, ADAMTS-1 behaves as 
protumor or tumor-suppressor metalloprotease depending 
on different factors. For instance, ADAMTS-1 functions 
as a protumor protease if it is produced by stroma-
derived cells, but not when produced by tumor cells [43]. 
In addition, anti-angiogenic activity associated to 
ADAMTS-1 promotes inhibition of liver metastasis 
but not lung metastasis [44]. Consequently, interactions 
between ADAMTSs and fibulins could be an additional 
feature that influence the different behavior displayed by 
ADAMTSs depending on the tissue or cell type where they 
are produced. Also, it remains to know whether Fibulin-2 
could also act in a similar manner than Fibulin-1 does on 
ADAMTS-1 activity.
We have also explored the consequences of Fibulin-2 
degradation within the tumor extracellular matrix. In fact, 
Fibulin-2 can act as a physical barrier hampering the 
dissemination of cancer cells in breast tumors and thereby 
loss of its expression has been associated with progression 
of cancer cells [12]. Our data using the poorly invasive 
breast cancer cell lines MCF-7 and T47D point out that 
protective role of Fibulin-2 could also be abolished 
through its degradation by ADAMTS-5. This effect 
would be especially relevant it those tissues containing 
high levels of Fibulin-2. In this regard, immunostaining 
of breast cancer tissues samples underlines the close 
proximity or partial co-localization of Fibulin-2 and 
ADAMTS-5 in different areas of grade-III invasive ductal 
carcinomas. Moreover, ADAMTS-5 can also be detected 
at the periphery of Fibulin-2, thus allowing to speculate 
that Fibulin-2 proteolytic fragments could increase their 
solubility making their detection more difficult. Western 
blot analysis using a set of normal-tumor paired samples 
also revealed that ADAMTS-5 is highly expressed in the 
tumor samples analyzed. Similarly, Gu et al. [45] have 
recently found that ADAMTS-5 is highly expressed in 
non-small cell lung cancer samples as compared with their 
paired adjacent non-tumor tissue. This elevated expression 
was associated with an enhancement of migration and 
invasion of malignant cells in this type of tumors, and 
with a poor prognosis of the affected patients. These data 
would indicate that ADAMTS-5 may act as metastatic 
promoter in tumors of different origins. In reference to 
Fibulin-2, our results indicate that is mainly detected in 
normal breast tissue, as has been previously reported by Yi 
et al. [12]. It is noticeable that some samples showed that 
Fibulin-2 is proteolytically processed, which can be due to 
the activity of ADAMTS-5 attending to the presence of a 
immunoreactive band of approximately 50 kDa. However, 
it cannot be ruled out that other enzymes also contribute 
to degrade Fibulin-2 in tumor processes [15]. For instance, 
gelatinases MMP-2 and MMP-9 are highly associated 
with tumor progression and both can effectively cleave 
Fibulin-2 [18]. In this work we have compared Fibulin-2 
digestion pattern generated by MMP-2 with that produced 
by ADAMTS-5 activity concluding that Fibulin-2 might 
Figure 4: Immunohistochemical analysis of Fibulin-2 and ADAMTS-5 expression in breast cancer specimens. 
Representative examples of invasive ductal breast carcinomas (IDC) at different stages (A and B, I; C and D, I–II; E and F, II; G and H, 
II–III; and I, J, K and L, III) showing staining for Fibulin-2 and ADAMTS-5. Negative controls (Neg.) are on the right.
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be a substrate for both metalloproteases in breast cancer. 
Interestingly, it has been widely shown that MMPs and 
ADAMTSs share the ability to cleave other extracellular 
components as is the case of aggrecan. In fact, cartilage 
aggrecan can be degraded within the interglobular domain 
but with different specificities and efficiencies [46]. It 
is also worth to mention that other factors can influence 
the activity of ADAMTS-5 on Fibulin-2 as can been the 
presence of TIMPs. In special, TIMP-3, a potent inhibitor 
of ADAMTS-5 [47], has been previously identified in 
breast cancer samples [48]. Consequently ADAMTS-5 
could remain inactivate despite of its high expression in 
some tumor tissues samples. These extracellular matrix 
components and their biological effects highlight the 
molecular complexity and heterogeneity of the tumor 
microenvironment.
We also wanted to evaluate whether a potential 
degradation of Fibulin-2 by ADAMTS-5 could promote 
other changes in the tumor microenvironment. To this 
end we generated  fibroblast spheroids, which have been 
successfully employed to investigate different aspects 
concerning the crosstalk between tumors cells and 
their surrounding stroma [49–51]. We found that that 
conditioned medium from MCF-7 cells overproducing 
both extracellular matrix proteins clearly induces an 
increase of the migratory and invasive properties of 
mammary fibroblasts when cultured as spheroids in 
3D collagen matrices as compared with the effect of 
conditioned medium from MCF-7 overproducing Fibulin-2 
alone. This pro-invasive effect was similar but less 
pronounced than that for spheroids cultured in the presence 
of conditioned medium from MCF-7 cell overproducing 
ADAMTS-5 alone. This result could also indicate that 
ADAMTS-5 exhibits a potent chemotactic activity to 
recruit fibroblasts as has been previously demonstrated 
for ADAMTS-1 [44]. In this sense, we observed an 
increase in the α-SMA levels in mammary fibroblasts 
when exposed to conditioned medium from MCF-7 
Figure 5: Fluorescent immunostaining of ADAMTS-5 and Fibulin-2 in invasive ductal breast carcinoma and western 
blot analysis of paired normal-tumor breast cancer tissue samples. (A and B), detection of ADAMTS-5 (green); and (C and D), 
detection of Fibulin-2 (red). (E and F), merged images. (G and H), show merged images counterstained with DAPI to localize the nucleus. 
I, detection of Fibulin-2 and ADAMTS-5 by western blot in a set of eight matched normal (N) and tumor (T) breast cancer samples. (#2, 
grade I;  #5 and #12, grade I–II; #11, #15 and #16, grade II; #13 and #14, grade III). Molecular weight markers are on the left and Ponceau 
S staining was employed to assess protein loading.
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Figure 6: ADAMTS-12 blocks digestion of Fibulin-2 by ADAMTS-5. (A) Fibulin-2 was incubated with ADAMTS-5 in the 
presence (+) or absence (−) of ADAMTS-12 at 0, 8 and 16 h, and results were examined by western blot. (B) Presence of ADAMTS-12 
decreases the ability of SK-BR-3 overproducing ADAMTS-5 to invade. Left, representative pictures showing the invasive SK-BR-3 
cells using Matrigel-coated invasion chambers. SK-BR-3c indicates cells transfected with an empty vector; ADAMTS-5, SK-BR-3 cells 
expressing exogenous ADAMTS-5; ADAMTS-12 indicates cells expressing exogenous ADAMTS-12, and ADAMTS-5 + ADAMTS-12 
indicates SK-BR-3 cells expressing both metalloproteases as is indicated in the center panel (β-actin was employed as loading control). 
Right, quantification of fold-change in invasion capacity of SK-BR-3 cells under the different conditions assayed. (C) Proposed models 
for the influence of the examined ADAMTS metalloproteases in the progression of breast cancer. Left, secretion of ADAMTS-4 and 
particularly of ADAMTS-5 by tumor cells can contribute to cleave Fibulin-2 thus leading to cancer cell spreading and an increase of the 
migratory potential of the fibroblasts. Right, ADAMTS-12 may act as a tumor-protective metalloprotease through the interaction with 
Fibulin-2. This interaction may impede digestion of Fibulin-2 by aggrecanases thus hindering progression of tumor cells.
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overproducing Fibulin-2 and ADAMTS-5, effect that can 
be related to a fibroblast activation. Thus, it can be inferred 
that simultaneous presence of Fibulin-2 and ADAMTS-5 
can actively modify cellular behavior of breast cancer cells 
as well as the surrounding mammary fibroblasts, which 
represent a major and crucial component of tumor stroma. 
In this work we have also found that ADAMTS-12 can 
inhibit Fibulin-2 degradation. ADAMTS-12 is mainly 
produced by stromal cells at the earliest stages not only of 
breast tumors [31] but also of colon cancer [52, 53]. Our 
new data support that the protection that ADAMTS-12 
exerts on Fibulin-2 degradation by aggrecanases might 
form part of a defensive response against tumor invasion 
by strengthening the physical barrier created by Fibulin-2 
and its interacting partners. Consequently, a decrease 
in expression levels of ADAMTS-12 in more advanced 
stages of the disease, such as those analyzed in this work, 
would contribute to the spreading of tumor cells.
More functional and clinical studies are needed 
to fully understand the participation of ADAMTS-5 in 
tumor processes. Thus, it would be crucial to distinguish 
processes in which ADAMTS-5 acts as an antitumor 
protein through its angio-inhibitory activity [54], from 
those protumor actions in which its proteolytic function 
seems to be crucial. Also, it remains to investigate 
whether any Fibulin-2 proteolytic fragment promotes 
bioactive functions as happens with versikine, a fragment 
containing the N-terminal G1 domain of versican and 
that is generated by the proteolytic activity or certain 
ADAMTSs including ADAMTS-5 [55]. In the case of 
Fibulin-2, a potential bioactive fragment should comprise 
a region near the N-terminus of the protein attending to 
the localization of the epitope (mapping between amino 
acids 28 and 277). These future challenges will help to 
determine how the relationship between Fibulin-2 and 
ADAMTS metalloproteases could also influence the 
tumor-protective role associated to Fibulin-2 in other 
types of tumors such as nasopharyngeal carcinomas [11]; 
or the tumor-promoting functions of Fibulin-2 in lung 
cancer [10]. In the meantime, degradation or protection 
of Fibulin-2 by ADAMTS metalloproteases provide new 
insights into the molecular mechanisms governing cellular 
microenvironment in normal and pathological conditions. 
MATERIALS AND METHODS
Cell lines and cell culture conditions
Human breast cancer cell lines MCF-7, T47D and 
the human embryonic kidney cell line HEK 293 were 
kindly provided by Dr. Carlos Lopez-Otin, Universidad 
de Oviedo, Spain. SK-BR-3 was obtained from ATCC. 
Cells were cultured in DMEM supplemented with 10% 
fetal bovine serum, 50 μg/mL streptomycin and 100 U/mL 
penicillin (Life Technologies). Human mammary 
fibroblasts were purchased from Innoprot. For transfection 
experiments, vectors containing full-length human cDNA 
for ADAMTS-1 (Origene, ref. RC205984), ADAMTS-4 
(Origene, ref. RC209226), ADAMTS-5 (Origene, ref. 
RC210834) and Fibulin-2 (cDNA clon HK9, kindly 
provided by Dr. T. Sasaki, Oita University, Japan) [3] 
were transfected into cells at 70–80% confluence using 
TransIT-X2 Dynamic Delivery System (Mirus). Cells 
stably producing recombinant proteins were selected in 
the presence of 500 μg/ml of geneticin (Sigma-Aldrich).
Western blot analysis
For western blot analysis, cell extracts were 
resolved by 10% gel electrophoresis and transferred to 
polyvinylidene difluoride (PVDF) membranes (Millipore). 
When indicated, recombinant ADAMTS-1,  ADAMTS-4 
and ADAMTS-5 were detected using a primary anti-
FLAG antibody (Sigma-Aldrich). Anti-Fibulin-2 (H-250) 
and anti-ADAMTS-5 (H-200) antibodies were from 
Santa Cruz Biotechnology, and anti ADAMTS-12 was 
from Proteintech. Anti-β-actin, Anti-β-tubulin and anti-
α-SMA antibodies were from Sigma-Aldrich. In the 
case of HEK293 cells, 1 ml of conditioned medium was 
precipitated with four volumes of cold acetone, placed in 
freezer for 1 hour, centrifugated at 1000 × g for 10 min, and 
the pellet was resuspended in 2× SDS-PAGE loading buffer. 
Immunoreactive proteins were visualized using HRP-
peroxidase labeled anti-rabbit or anti-mouse secondary 
antibodies and the ECL detection system (Pierce). 
Invasion assay
Invasion potential of T47D and MCF-7 cells was 
evaluated using 24- well Matrigel-coated invasion chambers 
with a 8 μm pore size (BD Biosciences) and at least three 
independent experiments were performed for each condition. 
To this end, 1.2 × 105 cells were allowed to migrate for 96 h 
using 10% foetal bovine serum as a chemoattractant. 
Cells that reached the lower surface were fixed with 4% 
paraformaldehyde and stained with crystal violet. Total 
number of cells in the lower chamber was determined by 
visible light microscopy (LAS EZ 2.0 Leica, Microsystems). 
In the case of SK-BR-3 cells, invasion assay was performed 
as above but effect of the exogenous expression of 
ADAMTS-12 in cell migration was also probed. 
Enzymatic assay
Proteolytic assay on Fibulin-2 (0.5 μg  per reaction, 
kindly provided by Dr. T. Sasaki, Oita University, Japan; 
or purchased from Abnova, ref. 28–1184), was carried out 
in 50 µL of reaction buffer (50 mM Tris-HCl, 150 mM 
NaCl, 10 mM CaCl2, 0.05% Brij 35, pH 8.5). Recombinant 
ADAMTS-1, ADAMTS-4, ADAMTS-5 and MMP-2 
were purchased from R&D Systems and employed at 
50 nM. Reactions were allowed to proceed at 37°C for the 
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indicated times and stopped by addition of reducing SDS-
sample buffer containing 20 mM EDTA. Then, digestion 
products were visualized by Western blot as described 
above. When indicated, samples were preincubated with 
ADAMTS-12 for 30 min before addition of ADAMTS-5. 
Production and purification of recombinant ADAMTS-12 
was performed as previously described [56]. 
Three dimensional sphere invasion assay
Human mammary fibroblasts were suspended in 
DMEM plus 5% Methyl cellulose (Sigma) at 2000 cells/ 
25 μl medium. Cell spheroids were subsequently obtained 
by serial pipetting of 25 μl into a non-adhesive bacterial 
Petri dish (2000 cells/ spheroid) and incubated in an 
inverted position for 18 hours. Next day, each cell spheroid 
was transferred to an individual well of a 96-well plate 
and embedded into 110 μL of 2.3 mg/mL bovine collagen 
matrix (Advanced Biomatrix PureCol). After two hours 
polymerization at 37°C, each well was filled with 100 μL 
of control medium or the indicated conditioned medium. 
Collective cell invasion was monitored using a Zeiss Cell 
Observer Live Imaging microscope (Zeiss, Thornwood, 
NY) coupled with a CO2 and temperature-maintenance 
system. Time-lapse images were acquired every 30 min 
during 20 h using a Zeiss AxioCam MRc camera. The 
invasive area was determined by calculating the difference 
between the final area (t = 20 h) and the initial area (t = 0 h) 
using image J analysis program.
Breast tissue samples
A breast tissue array containing 48 tumors samples 
of invasive ductal breast carcinoma from different tumor 
stages and three normal breast tissues was employed to 
examine the localization of ADAMTS-5 and Fibulin-2 
in human breast samples. Histological diagnosis was 
carried out by an experienced pathologist and all 
protocols were approved by the Ethics Committee of 
the Hospital Universitario Central de Asturias for the 
project PI11/2011. Written informed consent was obtained 
from the patients. Slides were processed for indirect 
peroxidase immunohistochemistry. To this end, sections 
were deparaffinized and rehydrated, and then rinsed in 
phosphate buffered saline (PBS) containing 1% tween-20. 
Santa Cruz Biotechnology antibodies were used for the 
detection of Fibulin-2 (H-250) and ADAMTS-5 (D-16), 
and samples were heated in high pH Envision FLEX 
target retrieval solution at 80°C for 20 min and then 
incubated for 20 min at room temperature in the same 
solution. Endogenous peroxidase activity (3% H2O2) 
and non-specific binding (33% fetal calf serum) were 
blocked and the sections were incubated overnight at 4°C 
with primary antibodies described above using a 1:100 
dilution for both antibodies. As secondary antibodies we 
used labeled polymer-HRP ready to use from DAKO. 
3-3′ diaminobenzidine was employed as a chromogen. 
Selected slides were counterstained with haematoxylin. 
For fluorescence microscopy, serial sections, 8 µm 
thick, from IDC grade III, were processed for double 
immunofluorescence using primary antibodies against 
Fibulin-2 and Alexa 448-conjugated goat anti-rabbit IgG 
secondary antibodies (BioRad, 1:500 dilution). In the 
case of ADAMTS-5, incubation with primary antibody 
was followed by a bridge mouse anti-rabbit IgG antibody 
(Thermo Fisher Scientific, 1:100 dilution) and then by a 
CyTM3-conjugated donkey anti-mouse secondary antibody 
from Jackson-ImmunoResearch (1:100 dilution). In 
addition, nuclei were stained with DAPI (4′,6-diamidino-
2-phenylindole) to ascertain structural details. Specificity 
of immunoreactivity was tested by omitting the primary 
antibodies or by replacing them with a non-immune serum.
Six breast tumor samples and a set of eight pairs of 
matched normal and tumor breast cancer tissue samples 
were also analyzed by western blot. To this end, samples 
were homogenized in a buffer containing 20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100 (Sigma-
Aldrich), 10 mM EDTA and Complete protease inhibitor 
cocktail (Applied Science). Tissue extracts were centrifuged 
at 15,000 × g at 4°C, supernatant collected and protein 
concentration was determined by the BCA protein assay kit 
(Pierce Biotechnology). Then, 20 µg of protein was resolved 
by gel electrophoresis and transferred to polyvinylidene 
difluoride (PVDF) membranes as indicate above. Staining 
of PVDF membranes with Ponceau S solution (Sigma-
Aldrich) was employed to examine protein loading.
Statistical analysis
Data were analyzed using Microsoft Excel and 
represented as means +/− S.E. Significant differences 
were determined with the Student t test and p values under 
0.05 were considered statistically significant (p < 0.05, 
*p < 0.01, **p < 0.005, ***).
Abbreviations
ECM; extracellular matrix; MMP, matrix 
metalloproteinase; ADAMTS, a disintegrin and 
metalloprotease with thrombospondin motifs; TIMP, tissue 
inhibitor of metalloprotease; α-sma, alpha smooth muscle 
actin.
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